Evidence map›Paper›PMID 35018520›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.

Shana S Jacobs, Jeffrey S Dome, Jiaxiang Gai, Andrea M Gross, Elena Postell, Pamela S Hinds, Lionel Davenport, John N van den Anker, Catriona Mowbray

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Guideline
  2. CYP2D6 genotype and associated 5-HTClinical and translational science · 2025
    Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shana S JacobsDivision of Oncology, Children's National Hospital, Washington, DC, USA. ssjacobs@childrensnational.org.
Jeffrey S DomeDivision of Oncology, Children's National Hospital, Washington, DC, USA.
Jiaxiang GaiBiostatistics and Study Methodology Department, Children's National Hospital, Washington, DC, USA.
Andrea M GrossPediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Elena PostellDivision of Oncology, Children's National Hospital, Washington, DC, USA.
Pamela S HindsGeorge Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Lionel DavenportDivision of Pathology and Lab Medicine, Molecular Diagnostics, Children's National Hospital, Washington, DC, USA.
John N van den AnkerDivision of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
Catriona MowbrayDivision of Oncology, Children's National Hospital, Washington, DC, USA.
Children's National · USGeorge Washington University · USNational Cancer Institute · US

Funding

Clinical and Translational Science Institute at Childrens NationalUL1TR001876 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI BELL, MICHAEL J · 2016 to 2021
$25.6M
Clinical and Translational Science Institute at Childrens National-Mentored Career Development CoreKL2TR001877 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI LUBAN, NAOMI L · 2016 to 2020
$2.0M
NIH HHS KL2TR001877NIH HHS UL1TR001876
6 · The paper itself

Abstract

purposeChemotherapy-induced nausea and vomiting (CINV) is a frequently seen burdensome adverse event of cancer therapy. The 5-HT3 receptor antagonist ondansetron has improved the rates of CINV but, unfortunately, up to 30% of patients do not obtain satisfactory control. This study examined whether genetic variations in a relevant drug-metabolizing enzyme (CYP2D6), transporter (ABCB1), or receptor (5-HT3) were associated with ondansetron failure.

methodsDNA was extracted from blood and used to genotype: ABCB1 (3435C > T (rs1045642) and G2677A/T (rs2032582)), 5-HT3RB (rs3758987 T > C and rs45460698 (delAAG/dupAAG)), and CYP2D6 variants. Ondansetron failure was determined by review of the medical records and by patient-reported outcomes (PROs).

resultsOne hundred twenty-nine patients were approached; 103 consented. Participants were less than 1 to 33 years (mean 6.85). A total of 39.8% was female, 58.3% was White (22.3% Black, 19.4% other), and 24.3% was Hispanic. A majority had leukemia or lymphoma, and 41 (39.8%) met the definition of ondansetron failure. Of variants tested, rs45460698 independently showed a significant difference in risk of ondansetron failure between a mutant (any deletion) and normal allele (p = 0.0281, OR 2.67). Age and BMI were both predictive of ondansetron failure (age > 12 (OR 1.12, p = 0.0012) and higher BMI (OR 1.13, p = 0.0119)). In multivariate analysis, age > 12 was highly predictive of ondansetron failure (OR 7.108, p = 0.0008). rs45460698 was predictive when combined with an increased nausea phenotype variant of rs1045642 (OR 3.45, p = 0.0426).

conclusionSelect phenotypes of 5-HT3RB and ABCB1, age, and potentially BMI can help predict increased risk for CINV in a diverse pediatric oncology population.

Indexed as

AntiemeticsNeoplasmsFemaleHumansNauseaOndansetronPharmacogeneticsVomitingAntiemeticsOndansetronChemotherapy-induced nauseaOndansetronPediatric cancerPharmacogenomics

Identifiers

PMID35018520
OpenAlexW4206704775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.